Vetio begins cannabis-based vet drug products

Vetio is a contract development and manufacturing company dedicated to animal health. It was just issued a cannabis research license by Health Canada.

“This is an important step in expanding our strategic Cannabis initiative to our full North American footprint, and is aligned with our mission of improving the lives of animals while assuring compliance of products to the highest industry standards,” said Mike Smith, vice president of Business Development. “With Cannabis R&D now in Montreal, our Jupiter, FL facility will remain focused on the development and manufacturing of Hemp-derived CBD liquid supplements and infused topical products.”

Vetio has a long history of veterinary drug development with nearly 40 scientists and engineers assisting clients in the registration and approval of novel and generic drug products through Health Canada, the FDA and other agencies around the world.

Vetio recently expanded its Montreal manufacturing capabilities for tablets, liquids, primary and secondary packaging, complex intermediate drug processing and palatants. 

Contract manufacturing at the Jupiter facility is dedicated to non-sterile topicals, otics, oral care and supplements for the companion, small animal and equine markets.